Abstract
A 23-valent polysaccharide pneumococcal vaccine (PPV) has been available in the UK for more than 20 years and is currently recommended for use in high-risk groups (HRG) of 2+ years of age. The degree of protection afforded by the PPV remains a critical issue, although a number of randomised clinical trials and case–control studies (CCS) have been published. The aim of this work is to review the estimates on the efficacy of PPV against pneumococcal pneumonia and invasive pneumococcal disease (IPD) in the elderly and to perform a meta-analysis in order to obtain a pooled estimate of the level of protection in high and low risk individuals. These two groups of individuals are at the centre of the current debate on whether or not to extend the vaccination programme to all elderly individuals 65+. Only randomised and quasi-randomised studies are included in the analysis and results are compared with previous meta-analyses. The effect of the inclusion of observational studies is investigated in the sensitivity analysis. When taken with the results of other meta-analyses and observational studies, it appears that PPV offers protection against IPD in the general elderly population (VE = 65%; 95% CI:−49–92%) whereas it has a moderate effect in the high-risk elderly (VE = 20%; 95% CI:−188–78%). The vaccine has little or no effect against pneumonia (VE = 16% in the general elderly and −20% in HRG).
Similar content being viewed by others
References
CDC. Prevention of pneumococcal disease: Recommendations of the advisory committee on immunisation practices (ACIP). MMWR 1997; 46(RR-08): 1-24.
Obaro SK, Monteil MA, Henderson DC. Fortnightly review: The pneumococcal problem. Br Med J 1996; 312: 1521.
Ortqvist A. Pneumococcal vaccination: Current and future issues. Eur Resp J 2001; 18: 184-195.
Salisbury DM, Begg NT. Immunisation against infectious disease, Bicentenary Edition. London: HMSO, 1996.
Fine MJ, Smith MA, Carson CA, Meffe F, Sankey SS, Weissfeld LA et al. Efficacy of pneumococcal vaccination in adults — A meta analysis of randomized controlled trials. Arch Intern Med 1994; 154: 2666-2677.
Moore RA, Wiffen PJ, Lipsky BA. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Fam Pract 2000; 1.
Hutchinson BG, Oxman AD, Shannon HS, Lioyd S, Altmayer CA, Thomas K. Clinical effectiveness of pneumococcal vaccine — Meta-analysis. Can Family Physician 1999; 45: 2381-2393.
Cornu C, Yzebe D, Leophonte P, Gaillat J, Boissel JP, Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: A metaanalysis of randomized trials. Vaccine 2001; 19: 4780-4790.
Rubins JB, Alter M, Loch J, Janoff EN. Determination of antibody responses of elderly adults to all 23 capsular polysaccharide after pneumococcal vaccination. Infect Immun 1999; 67: 5979-5984.
Leinonen M, Syrjala H, Jalonen E, Kujala P, Herva E. Demonstration of pneumolysin antibodies in circulating immune complexes — a new diagnostic method for pneumococcal pneumonia. Serodiag Immunother Inf Dis 1990; 4: 451-458.
Jadad A. Assessing the quality of reports of RCTs: Is blinding necessary? Control Clin Trials 1996; 17: 1-12.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
Johan Giesecke. Modern Infectious Disease Epidemiology. London: Edward Arnold, 1994.
Oxman AD, Cook DJ, Guyatt GH. Users' guides to the medical literature. VI. How to use an overview. Evidence-Based Medicine Working Group. JAMA 1994; 272: 1367-1371.
Kaufman P. Pneumonia in old age. Active immunisation against pneumonia with pneumococcus polysaccharide. Results of a six year study. Arch Intern Med 1947; 518-531.
Gaillat J, Zmirou D, Mallaret MR, Rouhan D, Bru JP, Stahl JP et al. Essai clinique du vaccin antipneumococcique chez des personnes agees vivant en institution. Rev Epidem Sante Publ 1985; 33: 437-444.
Honkanen P, Keistinen T, Miettinen L, Herva E, Sankilampi U, Laara E et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among elderly persons aged 65 years or older. Vaccine 1999; 17: 2493-2500.
Klastersky J, Mommen P, Cantraine F, Safary A. Placebo controlled pneumococcal immunization in patients with bronchogenic carcinoma. Eur J Cancer Clin Oncol 1986; 22: 807-813.
Koivula I, Sten M, Leinonen M, Makela H. Clinical efficacy of pneumococcal vaccine in the elderly: A randomized, single-blind population-based trial. Am J Med 1997; 103: 281-290.
Ortqvist A, Hedlund J, Burman LA, Elbel E, Hofer M, Leinonen M et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vacination Study Group. Lancet 1998; 351(9100): 399-403.
Davis AL, Aranda CP, Schiffman G, Christianson LC. Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease — a pilot study. Chest 1987; 92: 204-212.
Simberkoff MS, Cross AP, Al-Ibrahim M, Baltch AL. Efficacy of pneumococcal vaccine in high-risk patients — results of a veterans administration cooperative study. N Engl J Med 1986; 315: 1318-1327.
Leech JA, Gervais A, Ruben FL. Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. CMAJ 1987; 136: 361-365.
Riley ID, Andrews M, Howard R, Tarr PI, Pfeiffer M, Challands P. Immunisation with a polyvalent pneumococcal vaccine. Lancet 1977; 1338-1341.
Smit P, Oberholzer D, Hayden-Smith S. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 1977; 238: 2613-2616.
Austrian R, Douglas RM, Schiffman G. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physician 1976; 89: 184-194.
Shapiro ED, Clemens JD. A controlled evaluation of the protective efficacy of penumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med 1984; 101: 325-330.
Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325: 1453-1460.
Sims RV, Steinmann WC, McConville JH, King LR, Zwick WC, Schwartz JS. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 1988; 108: 653-657.
Farr BM, Johnston BL, Cobb DK, Fisch MJ, Germanson TP, Adal KA et al. Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. Arch Intern Med 1995; 155: 2336-2340.
Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy: An evaluation of current recommandations. JAMA 1993; 270: 1826-1831.
Forrester HL, Jahnigen DW, LaForce FM. Inefficacy of pneumococcal vaccine in high-risk population. Am J Med 1987; 83: 425-430.
Bolan G, Broome CV, Facklam RR, Plikaytis BD, Fraser DW, Schlech WF 3rd. Pneumococcal vaccine efficacy in selected populations in the United States. Ann Intern Med 1986; 104: 1-6.
Sisk JE, Moskowitz AJ, Whang W, Lin JD, Fedson DS, McBean AM et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997; 278: 1333-1339.
Ament A, Baltussen R, Duru G, Rigaud-Bully C, de Graeve D, Ortqvist A et al. Cost-effectiveness of pneumococcal vaccination of older people: A study in 5 European countries. Clin Inf Dis 2000; 31: 444-450.
Claxton K, Neumann PJ, Araki S, Weinstein M. Bayesian value-of-information analysis. An application to a policy model of Alzheimer's disease. Intern J Technol Assess Health Care 2001; 17: 38-55.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Melegaro, A., Edmunds, W.J. The 23-Valent Pneumococcal Polysaccharide Vaccine. Part I. Efficacy of PPV in the Elderly: A Comparison of Meta-Analyses. Eur J Epidemiol 19, 353–363 (2004). https://doi.org/10.1023/B:EJEP.0000024701.94769.98
Issue Date:
DOI: https://doi.org/10.1023/B:EJEP.0000024701.94769.98